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  The focus of previous research has demonstrated that both oat and yeast ß-glucan 
benefits immunosuppressed populations.  However, previous research has not, to our 
knowledge, investigated the effects of a yeast ß-glucan on the ummune functioning of 
healthy, free-living human populations.  PURPOSE: The goal of this research was to 
evaluate the effects of a yeast ß-glucan on symptoms of upper respiratory tract infection 
in healthy, free-living, college-aged males. METHODOLOGY: The WURSS-44, a 
reliable, validated survey used for determining symptoms of upper respiratory tract 
infection was filled out online daily by 79 male subjects between the ages of 18 and 40.  
Subjects were given a bottle of 250 mg capsules of either yeast ß-glucan or placebo to 
take daily.  RESULTS:  Yeast ß-glucan demonstrated no statistically significant effect 
on the experimental subject population for any of the variables associated with symptoms 
of upper respiratory tract infection. CONCLUSION: Yeast ß-glucan does not 
significantly improve immune functioning in healthy, free-living college aged males. 
 
Keywords: ß-glucan, immune, susceptibility, resistance 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1 
Table of Contents 
 
 Page 
Chapter One: Introduction 3  
Introduction 3 
Problem One 5 
Problem Two 6 
Research Hypotheses 6 
Significance of the Study 10 
Rationale of the Study 11 
Limitations 12 
Delimitations 13 
Definition of Terms 14 
  
Chapter Two: Review of Literature 15  
β-glucan 15 
Oat and Yeast β-glucan 16 
Upper Respiratory Tract Infections 20 
β-glucan and URTI 21 
Immune System Function 25 
Factors that Affect Immune Function 26 
College Students and Immune Function 30 
 
Chapter Three: Methodology 32 
Setting 32 
Subjects 32 
 
 
2 
Descriptive Data 32 
Exclusion Criteria 33 
Instrumentation 33 
Data Collection 34 
Statistical Procedures 40 
 
Chapter Four: Results 53 
Descriptive Data 53 
Wisconsin Upper Respiratory Symptom Survey 55 
SPSS 57 
 
References 59 
  
Chapter Five: Manuscript 67 
  
Appendix I 82  
Informed Consent Form 82 
 
Appendix II 85 
Background Survey 85 
Daily Survey 89 
 
 
 
 
 
 
 
 
3 
Chapter One: Introduction 
 
 
Introduction 
 
The immune system is a complex composition of cells and biological processes 
that acts to protect the body from foreign pathogens and emergent tumor cells.  The 
human body is an ideal host for bacteria, fungi, and viruses, and there is a constant battle 
between the evolving pathogens and the adaptation of the organism’s immune system to 
protect the body.  There are a number of pathogens that frequently escape the immune 
system’s first defenses, which can affect other systems.  Perhaps the most common area 
affected by the incidence of immune system failure to detect and eliminate a threat is the 
upper tract of the respiratory system.  The result is often what we call an upper 
respiratory tract infection (URTI), or the “common cold”.  Research done in 2002 
revealed that the average cold resulted in approximately 8.7 hours of work lost (Bramley 
et al., 2002).  Adults average 2-3 colds per year, which result in more than 45 million 
days of work lost in the United States alone (Barrett et al., 2007; Bramley et al. 2002).  
Lost productivity due to the common cold is estimated at over $25 billion per year 
(Bramley et al. 2002).  Research has been hard-pressed for decades to develop a clear 
understanding of the common cold, let alone a cure or successful treatment. 
There are a number of behaviors that have negative effects on the immune system 
including the lack of exercise (Pederson and Hoffman-Goetz, 2000), excessive amounts 
of exercise (Davis et al., 1997; Ceddia and Woods, 1999; Pederson and Hoffman-Goetz, 
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2000; Nieman, 2000; Nieman, 2003), poor nutrition habits (Beisel, 1996), lack of sleep 
(Dinges et al., 1995), and psychological stress (Wonnacott and Bonneau, 2002; Kiecolt-
Glaser, 1999).  College-aged students generally suffer any combination of these 
behaviors, which may cause them to suffer physiologically and academically as a result 
of getting an URTI (Tsai and Li, 2004). 
Since it is necessary to find methods of preventing URTI in humans, research has 
been directed to examine the effects of different supplements on immune function.  Over 
the past two decades, researchers have assessed the different affects of the carbohydrate 
ß-glucan on the immune system.  ß-glucan is a complex carbohydrate polymer found in 
the cell walls of plants. It has been shown to lower cholesterol in humans (Jenkins et al., 
2002), promote antitumor activity in both humans and mice (Vetvicka et al., 1996), and 
improve immune function in immunosuppressed populations of humans and mice (Yun et 
al., 2003; Brown and Gordon, 2003; Brown and Gordon, 2005).  The mode of ingestion 
for mice and humans is generally oral; however, some human research uses muscular 
injection.  There is some debate among current research as to whether or not ß-glucan can 
assist the immune system in preventing URTI (Nieman et al., 2008).  These debates 
generally arise because ß-glucan may have the most benefit in subjects who are clinically 
diagnosed as immunosuppressed (Vetvicka et al., 1996; Yun et al., 2003; Brown and 
Gordon, 2003; Brown and Gordon, 2005); however research is extremely limited in 
improvements in immune function in healthy, free-living, human populations.  Because 
the immune system can improve with moderate exercise (Nieman, 2003;) but may see 
deterioration with excessive and/or vigorous exercise (Davis et al., 1997; Ceddia and 
Woods, 1999; Pederson and Hoffman-Goetz, 2000; Nieman, 2000; Nieman, 2003), it is 
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difficult to determine the effects of ß-glucan in improving immune function in free-living 
humans (Nieman et al., 2008); especially young, active humans.  It is also possible that 
this phenomenon is problematic with lack of or excessive sleep and/or psychological 
stress. ß-glucan comes in many different forms such as oat, barley, rye, wheat, and yeast.  
Oat ß-glucan has been studied far more than any of the other forms and has been shown 
repeatedly to aid human physiological function in many ways (Jenkins et al., 2002; 
Vetvicka et al., 1996; Yun et al., 2003; Brown and Gordon, 2003; Brown and Gordon, 
2005).  The study of yeast ß-glucan is on the rise, but has struggled to demonstrate 
significant benefits at the level of oat ß-glucan. 
Because college-aged students generally have high amounts of perceived stress, 
vary in their amount of sleep and physical activity, and are more often exposed to viral 
and fungal infections due to group living situations, they may be an ideal population to 
examine symptoms of URTI and the potential benefits of ß-glucan supplementation.  
 
 
 
Problem One 
 
The first purpose of this study is to examine the effects of a yeast β-glucan 
supplement on symptoms of upper respiratory tract infection in college-aged males. 
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Problem Two 
 
 The second purpose of this study is to examine how time spent in sleep, 
psychological stress, time spent in physical activity, and exposure relate to duration and 
severity of an upper respiratory tract infection.  
 
 
 
Research Hypotheses 
 
 
Evaluation of Upper Respiratory Tract Infections and β-glucan 
 
 The present study used a reliable and valid survey to evaluate symptoms of URTI.  
Determination of an URTI was defined by the use of the survey as well as additional 
questions asked of the subjects.  Subjects were asked what they believed was the cause of 
their illness or symptoms in addition to the questions on the survey about symptoms of 
URTI.  If subjects believed the cause was an URTI, then the day was defined as a 
symptom day.  If, however the subject only met the criteria of the survey, the day was 
defined as a sick day.  The survey defined an URTI as two or more symptoms observed 
on any given day.  Episodes were defined as symptoms persisting for more than seven 
days.  We hypothesized that the individuals receiving the β-glucan supplement would not 
have a: 
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1. Reduced total number of symptom days of upper respiratory tract 
infection. 
2. Reduced symptom day severity score of upper respiratory tract infection. 
3. Reduced symptom day maximum severity score of upper respiratory tract 
infection. 
4. Reduced symptom day quality of life score of upper respiratory tract 
infection. 
5. Reduced symptom day maximum quality of life score of upper respiratory 
tract infection. 
6. Increased number of days before the first symptom day past 3 days of 
supplementation 
7. Reduced total number of sick days of upper respiratory tract infection. 
8. Reduced sick day severity score of upper respiratory tract infection. 
9. Reduced sick day maximum severity score of upper respiratory tract 
infection. 
10. Reduced sick day quality of life score of upper respiratory tract infection. 
11. Reduced sick day maximum quality of life score of upper respiratory tract 
infection. 
12. Increased number of days before the first sick day past the first three days 
of supplementation. 
13. Reduced total number of symptom episodes of upper respiratory tract 
infection. 
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14. Reduced symptom episode severity score of upper respiratory tract 
infection. 
15. Reduced symptom episode quality of life score of upper respiratory tract 
infection. 
16. Reduced symptom episode duration of upper respiratory tract infection. 
17. Reduced symptom episode maximum duration of upper respiratory tract 
infection. 
18. Increased number of days before the first symptom episode past the first 3 
days of supplementation. 
19. Reduced total number of sick episodes of upper respiratory tract infection. 
20. Reduced sick episode severity score of upper respiratory tract infection. 
21. Reduced sick episode quality of life score of upper respiratory tract 
infection. 
22. Reduced sick episode duration of upper respiratory tract infection. 
23. Reduced sick episode maximum duration of upper respiratory tract 
infection. 
24. Increased number of days before the first sick episode past the first 3 days 
of supplementation. 
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Evaluation of Upper Respiratory Tract Infections and Factors that Affect URTI Risk 
 
1. We hypothesized that individuals who sleep less will not have higher 
severity scores and effect on quality of life scores throughout the duration 
of an episode than those who sleep more. 
 
2. We hypothesized that individuals who have higher stress scores will have 
higher severity scores and effect on quality of life scores throughout the 
duration of an episode than those who have lower stress scores. 
 
 
Rationale for Hypothesis Two 
 
 Previous research has demonstrated that psychological stress increases 
blood cortisol levels (Tortora and Derrickson, 2006).  Cohen et al., 1991 
presented that increased blood cortisol levels and psychological stress are 
associated with an increased risk of acute infections of the upper 
respiratory tract. 
 
3. We hypothesized that individuals who get moderate amounts of exercise 
prior to and during an episode will have lower severity scores and quality 
of life scores through the duration of an episode than those who are 
generally sedentary and those who get vigorous amounts of exercise. 
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Rationale for Hypothesis Three 
 
 Previous research has shown that physical activity has varying effects on 
the immune system.  Generally, regular, moderate exercise improves 
immune function while extended vigorous exercise as well as no exercise 
has adverse effects on immune function (Nieman, 2003; Woods, 2005; 
Nieman, 2007).  
 
4. We hypothesized that individuals who have higher exposure scores prior 
to an episode will not have higher severity scores and quality of life 
throughout the duration of an episode. 
  
 
 
Significance of the Study 
 
 Previous research has concluded that excessive amounts of time and money are 
wasted every year attempting to prevent and remedy symptoms of upper respiratory tract 
infection.  ß-glucan has been demonstrated to improve immune function in many 
populations.  Studies show that lab measurements to indicate upper respiratory tract 
infections are not as accurate when compared to the individual’s perceived symptoms of 
upper respiratory tract infection (Jackson et al., 1957; Barrett et al., 2002; Barrett et al., 
2005; Barrett et al., 2007).  Barrett et al. (2007) found that treatments of the common cold 
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such as antihistimine, decongestants, steroids, zinc, vitamin C, and Echinacea did not 
decrease illness duration and ultimately cold remedies offer only limited benefits.  Most 
research agrees that oat ß-glucan can help prevent infection of the upper respiratory tract 
in clinically diagnosed immunosuppressed individuals, however, to our knowledge no 
research has succeeded in showing that a yeast ß-glucan supplement can improve 
symptoms of upper respiratory tract infection in relatively healthy populations. 
 
 
 
Rationale for the Study 
 
 Collecting survey data daily may allow for a more accurate picture of URTI in 
male college students throughout a semester.  Examining whether or not ß-glucan can 
prevent these symptoms may have implications for maintaining immune function in 
healthy, free-living populations.  Also, this research may provide a better understanding 
of how much each of the risk factors for URTI plays a role in preventing and fighting 
URTI.  
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Limitations 
 
i/Non-randomized sample.  Subjects were not from a randomized sample.  Subjects were 
recruited from The University of Montana campus.  Most were from classes in the 
Department of Health and Human Performance. 
 
ii/Participants. Although we aimed for socioeconomic diversity, our participants were 
volunteers and may not have been representative of cold-sufferers.   
 
iii/Age and Sex. The data collected only applies to college-aged males. 
 
iv/Survey. Qualitative, self-reported survey data, may have been biased. 
 
iv/Free-living individuals.  We did not control for lifestyle habits or dietary habits.  
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Delimitations 
 
i/Type of subjects.  Due to the large number of potential participants in the study 
population, the population involved in the current study focused only on students at The 
University of Montana. 
 
 
ii/Age of subjects. Due to problems with getting consent for persons under the age of 18, 
our age range began at 18 years.  Due to the differences in pulmonary function seen in 
older populations, our age range ended at 41 years. 
 
iii/Survey.  Survey instruments used only scale items and did not include many open-
ended response items. 
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Definition of Terms 
 
 
Immune System: the integrated body system of organs, tissues, cells, and cell products 
such as antibodies that differentiates self from non-self and neutralizes potentially 
pathogenic organisms or substances. 
Immunosuppression: the inhibition of the normal immune response because of disease, 
the administration of drugs, or surgery. 
 
Resistance: the ability to ward off damage or disease through immune defenses. 
 
Dietary Supplement: a product taken orally that contains one or more ingredients that 
are intended to supplement one's diet. 
 
Susceptibility: vulnerability or lack of resistance to illness. 
 
Upper respiratory tract infections: are the illnesses caused by an acute infection which 
involves the upper respiratory tract: nose, sinuses, pharynx or larynx. 
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Chapter Two: Review of Literature 
 
 
β-glucan 
 
 Fiber is a necessary part of the human diet.  ß-glucan is a type of fiber that is 
soluble, viscous, and fermentable.  There are six forms of ß-glucan found in the cell walls 
of green plants and some fungi.  Glucans are glucose polysaccharides containing one kind 
of simple sugar, or monosaccharide, glucose.  ß-glucans are made up of ß-bonds, which 
are more difficult to digest for some mammalian digestive tracts.   
The structure of ß-glucan is slightly different from source to source.  Generally, ß-
glucans are composed of linear (β-1  3) backbone chains with different side chains (β-1 
 4 or β-1  6) (Castro et al., 2007).  Cellulose is a source of (β-1  4)-ß-glucan, 
which is a long and linear polymer that is difficult for humans to digest.  Both oat and 
barley have mixed-linkage (β-1  3, β-1  4)-ß-glucans and are easily fermented in the 
intestine.  Other grains, such as wheat, rye, and rice, contain small amounts of ß-glucan.  
Microbial (β-1  3)-ß-glucan is another component of cell walls or can be secreted by 
microorganisms growing on or in plants, such as yeast.  Mushrooms also contain (β-1  
3)-ß-glucans, with (β-1  6) side chains.   
The percentage and distribution of ß-glucan in the source may also determine its 
structure.  Mushrooms typically contain 0.3% ß-glucan, whereas the distribution of the 
carbohydrate in grains range between 17% and 46%.  Generally, soluble ß-glucan content 
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is much higher in cereals than insoluble ß-glucan; in mushrooms and microorganisms this 
ratio varies (Manzi and Pizzoferrato, 2000).   
ß-glucan chemical structure is made up of mostly beta-bonds.  Human digestive 
enzymes can generally only break down α-bonds easily.  The human body can only break 
down these beta-bonds in mastication and in the lower gastrointestinal tract by bacterial 
enzymes (Whitney and Rolfes, 2002).  Soluble ß-glucans are theorized to translocate 
from the gastrointestinal tract into systemic circulation by uptake of Peyer’s patches, 
clusters of lymphoid tissue in the lower gastrointestinal tract (Rice et al., 2005).  
All forms of ß-glucan have demonstrated both null effect and improvements in all 
populations; rarely has it been shown to induce damage.  One study did find that using an 
altered form of oat ß-glucan, rather than leaving the ß-glucan in its most natural state, 
induced statistically significant damages to pulmonary function in immunosuppressed 
mice (Young et al., 2003).  Even toxicity level studies have failed to show significant 
results for toxic levels of consumed or injected ß-glucan.  Research in many areas of 
illness and chronic disease have recently been investigating potential benefits of different 
derivatives of ß-glucan supplementation. 
 
 
Oat and Yeast ß-glucan 
Cholesterol  
 
Oat ß-glucan has been studied in clinical trials, and has been identified as the 
component responsible for the significant cholesterol-lowering properties in oats; the 
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most attention is given to oat ß-glucan in its effectiveness to decrease low-density 
lipoprotein (LDL) cholesterol in human populations.  After 5 weeks of orally ingesting 
2.5 g of oat-derived ß-glucan twice daily, men and women were both seen to have lower 
LDL cholesterol than the control group (Naumann et al., 2006).  Similarly, Jenkins et al. 
(2002) found that hyperlipidemic patients who consumed more soluble fiber containing 
oat ß-glucan or psyllium (8 g per day or more) in their diet over a one month period 
decreased their LDL cholesterol significantly more than those who did not consume a 
high amount of soluble fiber in their diet. 
Yeast, has also been shown to lower LDL cholesterol in hyperlipidemic human 
populations.  Obese male patients were given 7.5 g of yeast-derived ß-glucan twice daily 
for a two-week period and lipid panels were measured.  Results showed a significant 
decrease in LDL cholesterol (Nicolosi et al., 1999). 
These complimentary results suggest that oat and yeast ß-glucan may follow 
similar pathways or may have similar mechanisms for decreasing LDL cholesterol in 
humans.  This parallel may indicate that the two may be comparable in affecting different 
aspects of human physiology. 
 
 
Cancer 
 
Oat ß-glucan may also help in cancer therapy by enhancing lung macrophage 
activity.  Murphy et al. (2004) discovered that oat ß-glucan can decrease the spread of 
melanoma cells and that these effects may be mediated by macrophage activity.  Mice 
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received 0.6 mg oat ß-glucan dissolved per 1 ml of drinking water daily for 10 days 
before tumor administration.  Results of this research show that the mice that were given 
an oat ß-glucan saw a significantly lower metastatic spread rate of the tumors.   
Yeast ß-glucan was shown to combine with and enhance an antibody, which 
fights a vascular endothelial cancer found in the human cervix (Salvador et al., 2008).  
The protocol consisted of screening and removing active tumor cells from living human 
females and implanted in immunodeficient mice.  Mice that received supplementation of 
1.2 mg of yeast-derived ß-glucan twice a week via intravenous injection, showed 
significantly reduced tumor size when compared with those that did not receive the 
supplementation.  The authors of this research suggest that, if the mechanism is similar in 
humans, cancer growth might be delayed by intravenous injection of yeast ß-glucan.  
Hong et al. (2004) also found that certain types of cancer cells were completely 
eliminated when yeast ß-glucan was orally administered to a similar murine population.  
These mice were given 400 µg of the yeast ß-glucan daily for three weeks. 
Supplementing with a yeast ß-glucan was also shown to stimulate proliferation 
and activation of peripheral blood monocytes in patients with advanced breast cancer 
(Demir et al., 2007).  The patients in the research were newly diagnosed or relapsed with 
metastatic breast cancer.  Each subject orally ingested 10 mg of yeast-derived ß-glucan 
for two weeks.  Peripheral blood was drawn at day 0 and day 15.  Although the majority 
of cancer fighting immune cells did not improve in any way, blood monocytes were 
shown to increase in number and amount of activity.  This study suggests that short-term 
treatment with yeast ß-glucan may improve blood monocyte number and function, which, 
in turn, indicates an improvement in immune function.  Both mice and human 
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populations suffering from various cancers have been shown to benefit from a yeast ß-
glucan supplement.  
Supplementation with an oat or yeast ß-glucan have both been successfully used 
in murine populations to slow tumor development.  The addition of human research 
demonstrating an improvement in blood monocyte number and function with yeast ß-
glucan implies that if the mechanisms and/or pathway of ß-glucan is similar in humans 
and mice, tumor activity may be semi-controlled with the aid of an oat or yeast ß-glucan 
supplementation.  Also, because this research supports that ß-glucan is translocated from 
the gut in humans into the blood stream, research in other areas of immune function are 
being conducted.  
 
 
Bacterial and Viral Infections 
 
Oat ß-glucan has also been found to fight certain infections in murine populations 
(Yun et al., 2003).    In this study mice were administered either intragastrically or 
intraperitoneally 3 mg of oat ß-glucan every other day for 10 days.  At 10 days, mice 
were exposed to either Staphylococcus aureus or Eimeria vermiformis.  These bacteria 
are known to cause similar, common infections in both mice and humans.  The 
experimental group was shown to have a lower mortality rate than the control group as 
well as an increased resistance to developing any infection.  This suggests that short-term 
treatment with an oat ß-glucan, prior to exposure, can enhance immune function against 
common infections in mice.   
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Similarly, Murphy et al. (2008) administered mice with 0.8 mg oat ß-glucan 
dissolved per 1 ml of drinking water for 10 days before inoculation with a virus.  In both 
studies, mice that orally ingested the oat ß-glucan demonstrated benefits in their immune 
function. 
 Promising research results investigating benefits of supplementation with oat ß-
glucan to aid in fighting infections has been shown.  Recently research has started to 
evaluate benefits of a yeast ß-glucan supplement in fighting infections, mainly URTI.  
Because similar results are seen between oat and yeast ß-glucan supplementation in 
cancer and cholesterol research in both mice and humans it is suggested that the two 
follow similar pathways in the murine and human bodies, have similar mechanisms in the 
two organisms, or both.  With the addition of successful research in showing that oat ß-
glucan supplementation is beneficial to the murine population in aiding the immune 
system in fighting infections, it is necessary to explore the murine and human population 
and effects of both oat and yeast ß-glucan supplementation in specific infections. 
 
 
Upper Respiratory Tract Infections 
 
 URTI and their symptoms are common and generally do not result in 
hospitalization or fatality.  However, because they are so common, money and time are 
spent excessively every year to prevent and treat symptoms of URTI (Bramley et al., 
2002).  The common cold, as URTI are generally known, can cause measurable, 
significant declines in quality of life (Linder and Singer, 2003).   
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There are many suggestions as to why immune function is suppressed enough to 
allow an URTI to thrive.  Nieman (2007) concludes that excessive physical activity is 
enough of a physiological stress that the body experiences many changes in immune 
function: drop in natural killer cells and T cells, decrease in T cell function, decrease in 
nasal neutrophil phagocytosis and mucociliary clearance, etc.  Because of these changes, 
the body is much more susceptible to upper respiratory tract infections.  Carbohydrate 
feeding may help the immune system in some ways to protect it from the damages caused 
by prolonged, vigorous exercise, but may not aid in preventing upper respiratory tract 
infections (Nieman, 2007).   
 
 
ß-glucan and Upper Respiratory Tract Infections 
Murine Subjects 
 
Mice are a useful model for studying effects on the immune system and URTI.  
They appear to be susceptible to similar stimuli for immunosuppression to humans.  For 
example, both psychological and physical stressors are shown to increase risk of upper 
respiratory tract infections in mice (Hunzeker et al., 2004).  Previous research has shown 
that mice participating in a single bout of prolonged, vigorous exercise are at a higher risk 
for upper respiratory tract infections than those who either underwent a short-term 
exercise or no exercise (Davis et al., 1997).  The results of this particular study 
demonstrated that lung alveolar macrophage activity was reduced in the mice that 
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exercised for long durations.  This research suggests that mice could serve as a model for 
risk of URTI in humans. 
ß-glucan and its effects on immune function and URTI research began with mice 
models.  Oat ß-glucan has been shown to enhance immunity in mice and prevent 
infection of the upper respiratory tract.  ß-glucan may play a key role in offsetting the risk 
for infection following exercise stress in mice (Murphy et al., 2008).  This research 
examined lung macrophage activity and proliferation in mice that were supplemented 
with oat ß-glucan.  The mice were given 0.8 mg of oat ß-glucan 10 days prior to trial 
days.  One group of mice was exercised to volitional fatigue three consecutive days after 
supplementation days.  Depletion of lung macrophages negated the positive effects of the 
oat ß-glucan post exercise.  Results of this study demonstrated that lung macrophage 
activity is partially responsible for mediating supplemental effects of oat ß-glucan on 
susceptibility to URTI.  Because macrophages and lymphocytes are important for 
immune function, these studies imply ß-glucan may improve the number or function of 
these immune cells, which may help fight or prevent the prevalence of URTI. 
Davis et al. (2003) reported that only moderate exercise and not supplemental oat 
ß-glucan significantly improved immune function.  Similar to other ß-glucan research 
done in mice, the subjects were given 0.6 mg of oat ß-glucan dissolved into every 1 ml of 
drinking water daily for 10 days prior to inoculation with a herpes virus.  Mice were 
exercised on a treadmill for 1 hour per day for 6 days after the 10-day supplementation 
period with oat ß-glucan.  Results showed no significant improvement with the oat ß-
glucan alone, but with exercise there were significant improvements in immune function. 
With the same research group, Murphy et al. (2007) demonstrated slightly 
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different results.  Male mice were given 0.6 mg of oat ß-glucan dissolved into every 1 ml 
of drinking water daily for 10 days prior to exercise trials.  Mice were divided into six 
groups (control, oat ß-glucan with no exercise, moderate exercise, oat ß-glucan with 
moderate exercise, fatiguing exercise, and oat ß-glucan with fatiguing exercise).  Results 
of this study showed that moderate exercise and oat ß-glucan supplementation increased 
neutrophil burst activity.  The control group and fatiguing exercise groups did not see an 
increase in immune cell function.  There was no additive benefit of the moderate exercise 
and the oat ß-glucan supplementation. 
These combined results suggest that supplementing with an oat ß-glucan is 
beneficial in mice immunocompromised by infection or tumor as well as healthy 
moderately exercised mice.  
Willment et al. (2001) found that the human receptor of ß-glucan is both 
structurally and functionally similar to the mouse receptor.  The mouse ß-glucan receptor, 
Dectin-1, is a type II transmembrane protein, as is the corresponding receptor in humans. 
These receptors are capable of recognizing a variety of (β-1  3, β-1  6) ß-glucans and 
can also recognize intact yeast. As we have found that both the mouse and human 
receptors recognize ß-glucans. The human and mouse ß-glucan receptors differ in that the 
transcript encoding the human receptor is alternatively spliced, which does not seem to 
have an effect on the ability of the receptor to recognize ß-glucan or intact yeast 
(Willment et al. 2001).  Other research found specific receptors of fungal ß-glucan 
(Dectin-1) were also functionally similar to the molecule found in mice (Herre et al., 
2004).  The receptors were shown to be similar on the surface of both mouse and human 
leukocytes and that they both recognize β-glucan.  The receptor recognizes and binds 
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cells of the immune system (T-lymphocytes and leukocytes).  This evidence, along with 
the beneficial effects of oat ß-glucan in mice, suggests that the effects of ß-glucan as aids 
in proliferation of immune cells in mice should have similar effects in humans.   
 
 
Human Subjects 
 
Human research has found that oat ß-glucan offset increased upper respiratory 
tract infection risk associated with exercise stress (Ceddia and Woods, 1999; Davis et al., 
2004).  Because exercise can both improve and degenerate immune function, it is 
difficult to demonstrate the effects of a ß-glucan supplement in healthy, free-living 
populations. 
Similar research has been conducted in humans as well with conflicting results 
(Nieman et al., 2008).  Trained male cyclists were randomized to an experimental or 
control group.  The experimental group received 5.6 g per day of an orally administered 
oat ß-glucan supplement 2 weeks before, during, and1 day after 3 day trial.  Trial 
consisted of cycling for 3 hours per day at approximately 57% maximal watts.  URTI 
symptoms were monitored during supplementation and for 2 weeks after trial.  Blood 
samples were collected before and after 2 week of supplementation, immediately after the 
3-h exercise bout on day 3, and 14 hours after exercise.  Immune cellular activity 
associated with fighting UTRI was assessed and no significant differences were found 
between the two groups. 
The similarities seen between oat and yeast ß-glucan in both murine and human 
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populations suggest that similar effects may be seen in other areas of physiology, such as 
immune function.  Research on the effects of yeast ß-glucan on symptoms of URTI are 
currently lacking in beneficial results.  URTI pose a complicated threat to the immune 
system in that symptoms are difficult to diagnose as well as the cause could be viral or 
bacterial infection.  Also, because free-living humans are exposed to much more diverse 
threats to their immune systems that lab living mice, it is likely more difficult to see 
effects of a ß-glucan supplement in human populations.  It is necessary to understand the 
human immune system and factors that may compromise its function in order to 
investigate whether a yeast ß-glucan  could potentially benefit healthy, free-living 
humans. 
   
 
Immune System Function 
 
 The immune system is the primary defense system of the body to ward of harmful 
agents and is vital in maintaining homeostasis.  This system is comprised of two 
developmental components: innate immunity and specific immunity.  Innate immunity is 
present at birth and provides immediate, but general protection against invasion by a 
number of different pathogens. Specific immunity develops more slowly and becomes a 
response mechanism activated by a specific invader.  The skin and mucous membranes of 
the human body provide the first line of defense and protection against these invaders.  
Gastric fluids, at a high acidity, allow digestion of food and kill many different types of 
bacteria found in the food ingested.  Antimicrobial proteins, phagocytes (neutrophils and 
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macrophages), natural killer cells, inflammation, and fever comprise the second line of 
defense against pathogens (Tortora and Derrickson, 2006).  The lymphatic system, 
working together with other systems of the body, makes up the immune system of the 
human body (Tortora and Derrickson, 2006). 
 If the first line of defense fails to identify and ward off foreign invaders, the 
second line of defense will take over.  While inflammation and fever work to eliminate a 
threat, antimicrobial proteins are produced in a number of ways by lymphocytes, 
macrophages, and fibroblasts and allow cells to prevent further replication of viruses 
(Medzhitov and Janeway, 1997).  Other proteins activated can cause cytolysis, or 
bursting, of microbes, promote phagocytosis, and contribute to inflammation.   Some 
proteins inhibit growth of bacteria by limiting the amount of iron available.  Natural killer 
cells attack any cells that display abnormal proteins.  These cells release a wide range of 
cell destruction enzymes and proteins in order to eliminate a threat.  Phagocytes target 
and ingest microbes or other cellular debris.  These cells can wander to sites of infection 
or remain stationary in different specific tissues.  Alveolar macrophages reside in lung 
tissue to prevent damage by foreign particles and protect against other unwanted 
pathogens (Medzhitov and Janeway, 1997; Tortora and Derrickson, 2006). 
 
 
Factors that Affect Immune Function 
 
 A disease or illness can be a result of a failure of the immune system to protect 
the body from pathogens or cancer cells.  Even though the immune system is complex 
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and highly developed, there are many pathogens that manage to surpass the body’s 
defenses, often resulting in disease or illness.  There are many behaviors which can result 
in a decline in immune function.   
 
 
Nutrition Behaviors 
 
Malnutrition and other poor nutritional habits can impact generalized host defense 
mechanisms (Beisel, 1996).  Children and the elderly are more susceptible to malnutrition 
than adults; however, immune function can be altered through all stages of life with poor 
nutrition habits, which include excessive nutrient intakes (Beisel, 1996).  Beisel (1996) 
concluded that lack of protein and vitamin A were whereas excess in caloric intake 
consisting of high fat content were both associated with immune compromise. 
 
 
Sleep Behaviors 
 
Sleep is a basic biological need in humans.  It is well known that sleep deprivation 
can have adverse effects on brain and motor function (Tortora and Derrickson, 2006).  
There is some debate in research as to whether partial or total sleep deprivation can be 
conceptualized as only being immunosuppressive (Dinges et al., 1995).  Experiments 
generally find significant changes in blood levels of immunity cells; however, not all 
changes in these levels can be considered negative for the immune system (Dinges et al., 
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1995).  Although there is a lack of conclusive evidence that sleep deprivation alone has 
adverse affects on the immune system, it may indirectly influence immune dysfunction 
with the combination of increased adrenal catecholamine release in the blood. 
 
 
Psychological Stress   
 
Cortisol is a hormone that has been associated with mental stress.  Cortisol has 
different effects on the human body including changes in the body such as inhibition of 
immune system activity (Tortora and Derrickson, 2006).  Psychological stress is also 
associated with an increased risk of acute infections of the upper respiratory tract (Cohen 
et al., 1991).  Sleep deprivation has been shown to cause cortisol blood level increases 
(Lac and Chamoux, 2003).  This combined evidence suggests that sleep deprivation can 
lead to an increase in psychological stress and cortisol, leading to a decline in immune 
function (Glaser and Kiecolt-Glaser, 2005; Fukuda and Morimoto, 2001; Kiecolt-Glaser, 
1999). 
 
 
Physical Stress 
 
Adrenal catecholamines are other stress hormones similar to cortisol in that they 
are all released from the adrenal cortex.  Physical and psychological stressors alter 
plasma catecholamine levels in different ways (Landmann et al., 1984).  Kohut et al. 
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(1998) found evidence that an increased release of adrenal catecholamines may cause a 
decrease in macrophage antiviral function following exercise.  Physical activity has 
sundry effects on the human body, which are dependent on intensity, frequency, and 
duration of sessions (Woods, 2005).  Generally, regular, moderate exercise improves 
immune function (Tortora and Derrickson, 2006; Gleeson, 2007) and is recommended as 
a strategy for managing stress (Nguyen-Michel et al., 2006), while extended, vigorous 
exercise and no exercise may have adverse affects on the immune system (Nieman, 2003; 
Woods, 2005; Nieman, 2007).  Immune function declines in similar ways between elite 
endurance athletes and a sedentary population (Nieman et al., 1995), which suggests that 
sedentary and extremely active populations may have similar immune function declines 
overall. 
Because of the wide range of changes seen in immune function due to sleep 
deprivation, psychological stress, physical activity, and poor nutrition habits, it is difficult 
to discern what the true mechanisms behind these changes are.  The evidence is 
conclusive, however, that both positive and negative changes in immune function are 
experienced due to any combination of these stressors.  It is beneficial to understand the 
variations between the different stressors and their effects on immunity.  Kiecolt-Glaser 
et al. (2002) discussed that that immune dysregulation may be one of the core 
mechanisms for a spectrum of conditions associated with cardiovascular disease, 
osteoporosis, arthritis, Type II diabetes, certain cancers, and other older-age-related 
functional declines. 
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College Students and Immune Function 
 
 Stress is a part of every person’s life.  As previously discussed, too much stress 
can have adverse affects on immune function.  College students experience a 
considerable amount of stress due to educational workload, financial difficulties, peer 
pressure, development of future plans, etc.  Generally, colleges require that a student live 
in a campus dorm for at least the first two years of school.  These close living conditions 
expose students to many different viral and bacterial infections, many of which affect the 
upper respiratory tract.  Research done in the 1990s suggested that college students’ 
amount of stress is negatively associated with self-concept, self-esteem (Goldman and 
Wong, 1997), and perceptions of performance in school (Garden, 1991).  Most research 
supports the conclusion that regular physical activity is a viable means of reducing stress 
in college students; however it is believed that extreme levels of stress discourages 
physical activity due to lack of time or energy in many college students, thus increasing 
perceived stress levels (Nguyen-Michel et al., 2006). 
 College students also have variable sleep patterns compared to other populations.  
Trockel et al. (2000) observed that college students with the most variable sleep patterns, 
particularly time of rising, accounted for the largest amount of variance in grade point 
average in college students living in residence halls.  Previous research has found that 
college students with poor sleep quality had greater schedule variability in the timing of 
social rhythms and activities with active social environment (Carney et al., 2006).  The 
authors of the previous study suggested also that quality of sleep is highly correlated with 
stress levels and thus, indirectly risk of URTI. 
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 Sleep, stress, physical activity, nutritional behaviors, and level of immune 
function are all factors that, when compromised, become a risk factor for developing an 
URTI.  Because of the variability of all of these factors, with the exception of immune 
function, college students are at a high risk for developing URTI.   Because college 
students are at high risk for UTRI and have healthy functioning immune systems, they 
represent a good sample population of healthy, free-living individuals.    
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Chapter Three: Methodology 
 
 
Setting  
All data collection was conducted through the Montana Center for Work 
Physiology and Exercise Metabolism on the campus of The University of Montana, 
Missoula, MT.  Survey data was collected using a secured online survey program 
(surveymonkey.com). 
 
 
Subjects 
 Approximately 175 males were initially recruited as the subjects in this 
investigation.  Of these recruits, 81 served as the subjects in the study.  These subjects 
were recruited through dorm communications, class recruitment presentations, and sign-
up in the University Center at The University of Montana.  Prior to participation, all 
subjects completed an Institutional Review Board (IRB) approved informed consent 
form. 
 
 
Descriptive Data 
 Descriptive Data was collected using four different methods.  (1) A background 
survey was completed by each subject which included age, gender, marital status, living 
conditions, injuries which limit physical activity, dieting, caffeine intake, tobacco use, 
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and estimated consumption of foods with high amounts of ß-glucan; (2) a daily survey 
completed by each subject during the twelve week study included twenty-four hour sleep 
record in hours, twenty-four hour physical activity time in minutes, and twenty-four hour 
stress level; and (3) an optional post study survey completed by the majority of subjects 
included current height, current weight, estimated weight prior to study, how often and/or 
easily subject accrues illness, and whether subject believed they were taking 250mg of ß-
glucan or placebo (rice flour). 
 
 
 
Exclusion Criteria 
 Subjects were excluded from the study results if (1) they were not within the 18-
41 year age requirement throughout the study; (2) they did not complete the background 
survey; or (3) they did not complete at least 75% (63) of the daily surveys. 
 
 
Instrumentation 
 
WURSS 
 The Wisconsin Upper Respiratory Symptoms Survey (WURSS) was developed as 
an evaluative illness specific quality-of-life instrument (Barrett et al., 2008).  The 
construct validity of the WURSS-44, a forty-four question version of the survey, is 
supported by measures of reliability and responsiveness of subjects (Barrett et al., 2005).  
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This survey looks at thirty-two symptoms of upper respiratory tract infection, ten 
functional quality-of-life items, one global illness severity item (How sick do you feel 
today?), and one item assessing global change (Compared to yesterday how do you feel?) 
(Barrett et al., 2005; Barrett et al., 2002).  The survey allows subjects to score their 
symptoms using a seven-point scale (0 = none, 1 = very mild, 3 = mile, 5 = moderate, 7 = 
severe). 
 
 
Data Collection 
 Each subject signed an Institutional Review Board (IRB) approved informed 
consent form prior to participation in the study.  Subjects were asked to take either a β-
glucan 250mg supplement or a placebo (rice flour) daily.  Distribution of supplement and 
placebo was done in a double-blind fashion.  Along with taking the daily supplement or 
placebo, each subject filled out an online survey (surveymonkey.com) which includes 
questions about sleep, stress, physical activity, exposure to illness, includes the WURSS, 
and asks a final question about the subject’s belief of the cause of any symptoms (flu, 
cold, allergies, etc.). 
 
Operational Definitions 
An upper respiratory tract infection symptom day was defined as any day that a 
subject (1) scored above a zero on the global illness severity question, (2) scored above a 
zero on at least two of the thirty-two symptoms of upper respiratory tract infection, and 
(3) believed that their symptoms were due to a cold. 
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Symptom day severity of an upper respiratory tract infection symptom day was 
defined as the total sum of all thirty-two symptom scores from the WURSS for each 
symptom day of a subject. 
 
Symptom day severity max of an upper respiratory tract infection symptom day 
was defined as the highest symptom day severity score for each individual subject. 
 
Symptom day quality of life severity of an upper respiratory tract infection 
symptom day was defined as the total sum of all ten effect on quality of life scores from 
the WURSS for each symptom day of a subject. 
 
Symptom day quality of life severity max of an upper respiratory tract infection 
symptom day was defined as the highest symptom day quality of life severity score for 
each individual subject. 
 
Number of days until first symptom day was defined as the total number of days 
prior to the first symptom day past the first seven days for each individual subject. 
 
An upper respiratory tract infection sick day was defined as any day that a subject 
(1) scored above a zero on the global illness severity question, (2) scored above a zero on 
at least two of the thirty-two symptoms of upper respiratory tract infection, and (3) 
believed that their symptoms were due to allergies, flu, cold, or other (specified). 
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Sick day severity of an upper respiratory tract infection symptom day was defined 
as the total sum of all thirty-two symptom scores from the WURSS for each sick day of a 
subject. 
 
Sick day severity max of an upper respiratory tract infection symptom day was 
defined as the highest sick day severity score for each individual subject. 
 
Sick day quality of life severity of an upper respiratory tract infection symptom 
day was defined as the total sum of all ten effect on quality of life scores from the 
WURSS for each sick day of a subject. 
 
Sick day quality of life severity max of an upper respiratory tract infection 
symptom day was defined as the highest sick day quality of life severity score for each 
individual subject. 
 
Number of days until first sick day was defined as the total number of days prior 
to the first sick day past the first seven days for each individual subject. 
 
An upper respiratory tract infection symptom episode was defined as a subject (1) 
scored above a zero on the global illness severity question for seven or more consecutive 
days, (2) scored above a zero on at least two of the thirty-two symptoms of upper 
respiratory tract infection, and (3) believed that their symptoms were due to a cold.  The 
end of a symptom episode was defined as two or more consecutive days where the 
 
 
37 
subject scored a zero on the global illness severity question.  If there was only one day 
when the subject scored a zero on the global illness severity question followed by one or 
more days of a score above zero with two or more symptoms, the episode was considered 
to be continuing.  If there were less than two symptoms in this case, the episode was 
classified as ended on the most recent symptom day when the subject scored above a zero 
on the global illness severity question with two or more symptom scored above zero. 
 
Symptom Episode symptom severity of an upper respiratory tract infection 
episode was defined as the average symptom day severity scores for each symptom 
episode of a subject. 
 
Symptom Episode quality of life severity of an upper respiratory tract infection 
episode was defined as the average symptom day quality of life severity scores for each 
symptom episode of a subject. 
 
Symptom Episode duration of an upper respiratory tract infection episode was 
defined as the total number of symptom days in a symptom episode.  This definition also 
included non-symptom days that are still considered part of a symptom episode. 
 
Symptom Episode duration max of an upper respiratory tract infection episode 
was defined as the highest symptom episode duration experienced by each subject. 
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Number of days until first symptom episode was defined as the total number of 
days prior to the first symptom episode past the first seven days for each individual 
subject. 
 
An upper respiratory tract infection sick episode was defined as a subject (1) 
scored above a zero on the global illness severity question for seven or more consecutive 
days, (2) scored above a zero on at least two of the thirty-two symptoms of upper 
respiratory tract infection, and (3) believed that their symptoms were due to allergies, flu, 
cold, or other (specified).  The end of a sick episode was defined as two or more 
consecutive days where the subject scored a zero on the global illness severity question.  
If there was only one day when the subject scored a zero on the global illness severity 
question followed by one or more days of a score above zero with two or more 
symptoms, the episode was considered to be continuing.  If there were less than two 
symptoms in this case, the episode was classified as ended on the most recent sick day 
when the subject scored above a zero on the global illness severity question with two or 
more symptom scored above zero. 
 
Sick Episode symptom severity of an upper respiratory tract infection episode was 
defined as the average symptom day severity scores for each sick episode of a subject. 
 
Sick Episode quality of life severity of an upper respiratory tract infection episode 
was defined as the average symptom day quality of life severity scores for each sick 
episode of a subject. 
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Sick Episode duration of an upper respiratory tract infection episode was defined 
as the total number of symptom days in a sick episode.  This definition also included non-
symptom days that are still considered part of a sick episode. 
 
Sick Episode duration max of an upper respiratory tract infection episode was 
defined as the highest sick episode duration experienced by each subject. 
 
Number of days until first sick episode was defined as the total number of days 
prior to the first sick episode past the first seven days for each individual subject. 
 
 
 
Data from the WURSS was collected daily to determine, as defined above, the (1) 
total number of symptom days for each subject, (2) average symptom day severity for 
each subject, (3) symptom day severity max for each subject, (4) average symptom day 
quality of life severity for each subject, (5) symptom day quality of life severity max for 
each subject, (6) total number of days prior to first symptom day for each subject (7) total 
number of sick days for each subject, (8) average sick day severity for each subject, (9) 
sick day severity max for each subject, (10) average sick day quality of life severity for 
each subject, (11) sick day quality of life severity max for each subject, (12) total number 
of days prior to first sick day for each subject (13) total number of symptom episodes for 
each subject, (14) average symptom episode severity for each subject, (15) average 
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symptom episode quality of life severity for each subject, (16) average symptom episode 
duration for each subject, (17) symptom episode duration max for each subject, (18) total 
number of days prior to first symptom episode for each subject (19) total number of sick 
episodes for each subject, (20) average sick episode severity for each subject, (21) 
average sick episode quality of life severity for each subject, (22) average sick episode 
duration for each subject, (23) sick episode duration max for each subject, (24) total 
number of days prior to first sick episode for each subject  
 
 
Compliance of subjects 
 
The study coordinator monitored subject compliance by telephoning or emailing 
subjects who missed three or more consecutive surveys.  Technological problems were 
resolved or subject was excluded at their own discretion.  Surveys were resent twice to 
non-responded subjects within two weeks of the originally sent daily survey date.  
 
 
Statistical Procedures 
 
 Background descriptive data were analyzed using an independent t-test for age, 
height (inches), pre-study weight (kg), post-study weight (kg), weight change (kg), 
physical activity time (minutes spent daily participating in aerobic, resistance, and 
organized sport activities, number of high school sports, caffeine intake (mg per week 
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from coffee, tea, or cola beverages), average sleep time (hours per night), average stress 
level (0-10; not stressed-extremely stressed), number of allergies, average estimated β-
glucan intake (servings per week total and servings per week of oatmeal, cereal with oats, 
other items with oats, barley, cereal with barley, other items with barley, mushrooms, 
whole wheat bread, whole wheat pasta, other whole wheat foods, rye bread, other rye 
foods) and will be expressed as Mean ±  SD.  For measures of daily sleep (hours per 
night), stress (0-10; not stressed-extremely stressed), and physical activity (aerobic 
exercise, resistance training, and organized sport; total physical activity minutes per day), 
and average score was calculated for each variable for each subject.  These measures 
were analyzed using an independent t-test.  Statistical significance was established at the 
p < 0.05 level.  These analyses were used to compare differences between the 
experimental group (supplement) and the control group (placebo). 
 
 
WURSS 
 
Total number of symptom days 
 
 Each subject had a total number of symptom days from the 12-week investigation 
(i.e. 0, 1, 2, etc.).  These data (indicating a total number of symptom days per participant) 
were analyzed using a 2-tailed, independent t-test (p < 0.05). 
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Average severity of symptom days 
 
 Each subject had an average symptom day severity score from the 12-week 
investigation.  These data (indicating an average severity score per participant) were 
analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Average symptom day severity max 
 
 Each subject had a maximum symptom day severity score from the 12-week 
investigation.  These data (indicating a maximum severity score per participant) were 
analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Average quality of life severity of symptom days 
 
 Each subject had an average symptom day quality of life severity score from the 
12-week investigation.  These data (indicating an average effect severity of symptom 
days on quality of life of each participant) were analyzed using a 2-tailed, independent t-
test (p < 0.05). 
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Average symptom day quality of life severity max 
 
 Each subject had a maximum symptom day quality of life severity score from the 
12-week investigation.  These data (indicating a maximum effect of symptom day 
severity on quality of life of each participant) were analyzed using a 2-tailed, independent 
t-test (p < 0.05). 
 
 
Total number of sick days 
 
 Each subject had a total number of sick days from the 12-week investigation (i.e. 
0, 1, 2, etc.).  These data (indicating a total number of sick days per participant) were 
analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Average severity of sick days 
 
 Each subject had an average sick day severity score from the 12-week 
investigation.  These data (indicating an average severity score per participant) were 
analyzed using a 2-tailed, independent t-test (p < 0.05). 
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Average symptom day severity max 
 
 Each subject had a maximum sick day severity score from the 12-week 
investigation.  These data (indicating a maximum severity score per participant) were 
analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Average quality of life severity of sick days 
 Each subject had an average sick day quality of life severity score from the 12-
week investigation.  These data (indicating an average effect severity of sick days on 
quality of life of each participant) were analyzed using a 2-tailed, independent t-test (p < 
0.05). 
 
 
Average sick day quality of life severity max 
 
 Each subject had a maximum sick day quality of life severity score from the 12-
week investigation.  These data (indicating a maximum effect of sick day severity on 
quality of life of each participant) were analyzed using a 2-tailed, independent t-test (p < 
0.05). 
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Total number of symptom episodes 
 
 Each subject had a total number of symptom episodes from the 12-week 
investigation (i.e. 0, 1, 2, etc.).  These data (indicating an average number of symptom 
episodes per participant) were analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Average symptom episode severity 
 
 Each subject had an average symptom episode severity score (average severity 
scores for symptom days in each episode) from the 12-week investigation.  These data 
(indicating an average severity score per symptom episode of each participant) were 
analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Average symptom episode quality of life severity 
 
Each subject had an average symptom episode quality of life severity score 
average quality of life severity scores for symptom days in each episode) from the 12-
week investigation.  These data (indicating an average quality of life severity score per 
symptom episode of each participant) were analyzed using a 2-tailed, independent t-test 
(p < 0.05). 
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Duration of symptom episodes 
 
 Each subject had an average symptom episode duration (average of total days for 
each symptom episode per participant) from the 12-week investigation.  These data 
(indicating an average number of days in each symptom episode per participant) were 
analyzed using a 2-tailed, independent t-test (p< 0.05). 
 
 
Maximum duration of symptom episodes 
 
 Each subject had a maximum symptom episode duration (symptom episode with 
highest number of days for each participant) from the 12-week investigation.  These data 
(indicating a maximum duration of symptom episodes) were analyzed using a 2-tailed, 
independent t-test (p< 0.05). 
Total number of sick episodes 
 
 Each subject had a total number of sick episodes from the 12-week investigation 
(i.e. 0, 1, 2, etc.).  These data (indicating an average number of sick episodes per 
participant) were analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
 
 
 
 
47 
Average sick episode severity 
 
 Each subject had an average sick episode severity score (average severity scores 
for sick days in each episode) from the 12-week investigation.  These data (indicating an 
average severity score per sick episode of each participant) were analyzed using a 2-
tailed, independent t-test (p < 0.05). 
 
 
Average sick episode quality of life severity 
 
Each subject had an average sick episode quality of life severity score average 
quality of life severity scores for sick days in each episode) from the 12-week 
investigation.  These data (indicating an average quality of life severity score per sick 
episode of each participant) were analyzed using a 2-tailed, independent t-test (p < 0.05). 
 
 
Duration of sick episodes 
 
 Each subject had an average sick episode duration (average of total days for each 
sick episode per participant) from the 12-week investigation.  These data (indicating an 
average number of days in each sick episode per participant) were analyzed using a 2-
tailed, independent t-test (p< 0.05). 
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Maximum duration of sick episodes 
 
 Each subject had a maximum sick episode duration (sick episode with highest 
number of days for each participant) from the 12-week investigation.  These data 
(indicating a maximum duration of sick episodes) were analyzed using a 2-tailed, 
independent t-test (p< 0.05). 
 
 
Symptom Episodes Severity Comparison 
 
 Average severity scores for corresponding symptom episode days starting at Day 
1 of each symptom episode were calculated for all symptom episode days for the two 
groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05).  
 
 
Symptom Episodes Quality of Life Comparison 
 
 Average quality of life scores for corresponding symptom episode days starting at 
Day 1 of each symptom episode were calculated for all symptom episode days for the 
two groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05). 
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Symptom Episode Exposure Comparison 
 
 Average exposure scores for corresponding symptom episode days starting at five 
days prior to Day 1 of each symptom episode were calculated for all symptom episode 
days for the two groups.  These data were analyzed using a 2-tailed, independent t-test 
(p<0.05). 
 
 
Symptom Episode Sleep Comparison 
 
 Average sleep scores for corresponding symptom episode days starting at five 
days prior to Day 1 of each symptom episode were calculated for all symptom episode 
days for the two groups.  These data were analyzed using a 2-tailed, independent t-test 
(p<0.05). 
 
 
Symptom Episode Stress Comparison 
 
 Average stress scores for corresponding symptom episode days starting at five 
days prior to Day 1 of each symptom episode were calculated for all symptom episode 
days for the two groups.  These data were analyzed using a 2-tailed, independent t-test 
(p<0.05). 
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Symptom Episode Physical Activity Comparison 
 
 Average physical activity scores for corresponding symptom episode days starting 
at five days prior to Day 1 of each symptom episode were calculated for all symptom 
episode days for the two groups.  These data were analyzed using a 2-tailed, independent 
t-test (p<0.05). 
 
 
Sick Episodes Severity Comparison 
 
 Average severity scores for corresponding sick episode days starting at five days 
prior to Day 1 of each sick episode were calculated for all sick episode days for the two 
groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05). 
 
 
Sick Episodes Quality of Life Comparison 
 
 Average quality of life scores for corresponding sick episode days starting at five 
days prior to Day 1 of each sick episode were calculated for all sick episode days for the 
two groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05). 
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Sick Episode Exposure Comparison 
 
Severity scores for corresponding sick episode days starting at five days prior to 
Day 1 of each sick episode were calculated for all sick episode days for the two groups.  
These data were analyzed using a 2-tailed, independent t-test (p<0.05). 
 
 
Sick Episode Sleep Comparison 
 
Average sleep scores for corresponding sick episode days starting at five days 
prior to Day 1 of each sick episode were calculated for all sick episode days for the two 
groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05). 
 
 
 
Sick Episode Stress Comparison 
 
Average stress scores for corresponding sick episode days starting at five days 
prior to Day 1 of each sick episode were calculated for all sick episode days for the two 
groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05). 
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Sick Episode Physical Activity Comparison 
 
Average physical activity scores for corresponding sick episode days starting at 
five days prior to Day 1 of each sick episode were calculated for all sick episode days for 
the two groups.  These data were analyzed using a 2-tailed, independent t-test (p<0.05).  
 
 
 
SPSS 
 
Symptom Episode Correlation  
 
A bivariate correlation matrix was calculated for Symptom Episode average 
severity scores, quality of life scores, sleep time, stress scores, physical activity time 
during the first five days of symptom episodes using SPSS (p<0.05). 
 
Sick Episode Correlation 
 
A bivariate correlation matrix was calculated for Sick Episode average severity 
scores, quality of life scores, sleep time, stress scores, physical activity time during the 
first five days of sick episodes using SPSS (p<0.05). 
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Chapter Four: Results 
 
 
Descriptive Data 
 
 Comparative baseline descriptive data are summarized in Table 1.  There were no 
significant differences between baseline descriptive data between groups.  For measures 
of pre-study and post-study weights there were no significant losses or gains for any 
subjects, thus weight is reported as an average weight of the group calculated from the 
average of each subject’s weight (kg) over the twelve weeks.  Comparative subject intake 
habits are summarized in Table 2.  There were no significant differences between groups 
with the exception of other food items consumed with oats (p = 0.02).  Comparative 
percent subject lifestyle characteristics are summarized in Table 3.  There were no 
significant differences between groups, with the exception of percentage of those who are 
single (p = 0.01) and those who are partnered (p = .05). 
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WURSS 
 Comparative data from the Wisconsin Upper Respiratory Symptom Survey are 
summarized in Table 4.  Yeast ß-glucan demonstrated no statistically significant effect 
on the subjects for any of the variables (number of symptom days, symptom day severity 
score, symptom day quality of life score, symptom day maximum severity score, 
symptom day maximum quality of life score, number of sick days, sick day severity 
score, sick day quality of life score, sick day maximum severity score, sick day maximum 
quality of life score, number of symptom episodes, number of sick episodes, average 
duration of symptom episodes, maximum duration of symptom episodes, average 
duration of sick episodes, maximum duration of sick episodes, symptom episode severity 
score, symptom episode quality of life score, sick episode severity score, and sick 
episodes quality of life score). 
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SPSS 
 
Symptom Episodes 
 
 The severity score and quality of life score are highly correlated with each other 
for symptom episodes.  Stress was the only independent variable that was correlated with 
both severity score and quality of life score during the first five days of the symptom 
episode.   
 
 
Symptom Episode Correlation 
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Sick Episodes 
 
The severity score and quality of life score are highly correlated with each other 
for sick episodes.  Stress was the only independent variable that was correlated with both 
severity score and quality of life score during the first five days of the sick episode.   
 
 
Sick Episode Correlation 
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ABSTRACT 
Purpose: The goal of this research was to evaluate the effects of a yeast ß-glucan on 
symptoms of upper respiratory tract infection in healthy, free-living, college-aged males. 
Methods: The WURSS-44, a reliable, validated survey used for determining symptoms 
of upper respiratory tract infection was filled out online daily by 79 male subjects 
between the ages of 18 and 40.  Subjects orally ingested 250 mg capsules of either yeast 
ß-glucan or placebo daily.  Results:  Yeast ß-glucan demonstrated no statistically 
significant effect on the experimental subject population for any of the variables 
associated with symptoms of upper respiratory tract infection. Conclusion: Yeast ß-
glucan does not significantly improve immune functioning in healthy, free-living college 
aged males. 
 
INTRODUCTION 
ß-glucan is a complex carbohydrate polymer found in the cell walls of plants that 
has been shown to lower cholesterol in humans (Jenkins et al., 2002), promote antitumor 
activity in both humans and mice (Vetvicka et al., 1996), and improve immune function 
in immunosuppressed populations of humans and mice (Yun et al., 2003; Brown and 
Gordon, 2003; Brown and Gordon, 2005).  Oat ß-glucan has been studied far more than 
any other forms and has been shown repeatedly to aid human physiological functioning 
(Jenkins et al., 2002; Vetvicka et al., 1996; Yun et al., 2003; Brown and Gordon, 2003; 
Brown and Gordon, 2005).   
Yun et al. (2003) argues that oat ß-glucan can alleviate certain infections in 
murine populations.  These mice were administered oat ß-glucan for 10 days and then 
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exposed to bacteria known to cause common upper respiratory tract infections in both 
mice and humans.  Similarly, Murphy et al. (2008) administered mice with oat ß-glucan 
dissolved per 1 ml of drinking water for 10 days before inoculation with a virus.  In both 
studies, mice that orally ingested the oat ß-glucan demonstrated benefits in their immune 
function.  The results suggest that short-term treatment with an oat ß-glucan, prior to 
exposure, can enhance immune function against common infections in mice.     
Supplementing with a yeast ß-glucan has been shown to stimulate proliferation 
and activation of peripheral blood monocytes in patients with advanced breast cancer 
(Demir et al., 2007).  Both mice and human populations suffering from various cancers 
have been shown to benefit from a yeast ß-glucan supplement.  Both oat and yeast ß-
glucan have been shown to decrease low-density lipoprotein (LDL) cholesterol in 
humans (Naumann et al., 2006; Nicolosi et al., 1999).    This parallel may indicate that 
oat and yeast ß-glucan may be comparable in affecting different aspects of human 
physiology. 
Both psychological and physical stressors are shown to increase risk of upper 
respiratory tract infections in mice and humans similarly (Davis et al., 1997; Nieman et 
al., 2008; Hunzeker et al., 2004).  Previous research has shown that mice participating in 
a single bout of prolonged, vigorous exercise are at a higher risk for upper respiratory 
tract infections than those who either underwent a short-term exercise or no exercise 
(Davis et al., 1997).  Oat ß-glucan has been shown to enhance immunity in mice and 
prevent infection of the upper respiratory tract.  Willment et al. (2001) found that the 
human receptor of ß-glucan is both structurally and functionally similar to the mouse 
receptor. 
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Human research has found that oat ß-glucan offset increased upper respiratory 
tract infection risk associated with exercise stress (Ceddia and Woods, 1999; Davis et al., 
2004).  The similarities seen between oat and yeast ß-glucan in both murine and human 
populations suggest that similar effects may be seen in other areas of physiology, such as 
immune function.  College-aged students generally suffer any combination of different 
health affecting behaviors, which may cause a weakened immune system and increased 
susceptibility to developing an URTI (Tsai and Li, 2004).  To our knowledge no research 
has succeeded in showing that a yeast ß-glucan supplement can improve symptoms of 
upper respiratory tract infection in relatively healthy populations.  Examining whether or 
not ß-glucan can prevent these symptoms may have implications for maintaining immune 
function in healthy, free-living populations.  This research may also provide a better 
understanding of how much each of the risk factors for URTI plays a role in preventing 
and fighting URTI.  The purpose of this study is to examine the effects of a yeast β-
glucan supplement on symptoms of upper respiratory tract infection in healthy, free-
living, college-aged males. 
We hypothesized that the yeast β-glucan supplement would have no effect on 
symptoms of upper respiratory tract infection in free-living, college-aged males. 
 
METHODS 
Subjects 
 There were 81 male, college-aged subjects in the study.  Prior to participation, all 
subjects completed an Institutional Review Board (IRB) approved informed consent form 
(Tables 1-3). 
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Descriptive Data 
 Descriptive Data was collected using four different methods.  (1) A background 
survey was completed by each subject which included age, gender, marital status, living 
conditions, injuries which limit physical activity, dieting, caffeine intake, tobacco use, 
and estimated consumption of foods with high amounts of ß-glucan; (2) a daily survey 
completed by each subject during the twelve week study included twenty-four hour sleep 
record in hours, twenty-four hour physical activity time in minutes, and twenty-four hour 
stress level; and (3) an optional post study survey completed by the majority of subjects 
included current height, current weight, estimated weight prior to study, how often and/or 
easily subject accrues illness.  Subjects were excluded from the study results if (1) they 
were not within the 18-41 year age requirement throughout the study; (2) they did not 
complete the background survey; or (3) they did not complete at least 75% (63) of the 
daily surveys. 
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Survey 
 Studies show that lab measurements to indicate upper respiratory tract infections 
are not as accurate when compared to the individual’s perceived symptoms of upper 
respiratory tract infection (Jackson et al., 1957; Barrett et al., 2002; Barrett et al., 2005; 
Barrett et al., 2007).  The Wisconsin Upper Respiratory Symptoms Survey (WURSS) 
was developed as an evaluative illness specific quality-of-life instrument (Barrett et al., 
2008).  The construct validity of the WURSS-44, a forty-four question version of the 
survey, is supported by measures of reliability and responsiveness of subjects (Barrett et 
al., 2005).  This survey looks at thirty-two symptoms of upper respiratory tract infection, 
ten functional quality-of-life items, one global illness severity item (How sick do you feel 
today?), and one item assessing global change (Compared to yesterday how do you feel?) 
(Barrett et al., 2005; Barrett et al., 2002).  The survey allows subjects to score their 
symptoms using a seven-point scale (0 = none, 1 = very mild, 3 = mile, 5 = moderate, 7 = 
severe). 
 
Data Collection 
 
 Each subject signed an Institutional Review Board (IRB) approved informed 
consent form prior to participation in the study.  Subjects were asked to take either a β-
glucan 250mg supplement or a placebo (rice flour) daily.  Distribution of supplement and 
placebo was done in a double-blind fashion.  Along with taking the daily supplement or 
placebo, each subject filled out an online survey (surveymonkey.com) which includes 
questions about sleep, stress, physical activity, exposure to illness, includes the WURSS, 
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and asks a final question about the subject’s belief of the cause of any symptoms (flu, 
cold, allergies, etc.). 
 
Statistical Procedures 
 
 Background descriptive data were analyzed using an independent t-test for age, 
height (inches), pre-study weight (kg), post-study weight (kg), weight change (kg), 
physical activity time (minutes spent daily participating in aerobic, resistance, and 
organized sport activities, number of high school sports, caffeine intake (mg per week 
from coffee, tea, or cola beverages), average sleep time (hours per night), average stress 
level (0-10; not stressed-extremely stressed), number of allergies, average estimated β-
glucan intake (servings per week total and servings per week of oatmeal, cereal with oats, 
other items with oats, barley, cereal with barley, other items with barley, mushrooms, 
whole wheat bread, whole wheat pasta, other whole wheat foods, rye bread, other rye 
foods) and will be expressed as Mean ±  SD.  For measures of daily sleep (hours per 
night), stress (0-10; not stressed-extremely stressed), and physical activity (aerobic 
exercise, resistance training, and organized sport; total physical activity minutes per day), 
and average score was calculated for each variable for each subject.  These measures 
were analyzed using an independent t-test.  Statistical significance was established at the 
p < 0.05 level.  These analyses were used to compare differences between the 
experimental group (supplement) and the control group (placebo). 
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RESULTS 
Comparative baseline descriptive data are summarized in Table 1.  There were no 
significant differences between baseline descriptive data between groups.  For measures 
of pre-study and post-study weights there were no significant losses or gains for any 
subjects, thus weight is reported as an average weight of the group calculated from the 
average of each subject’s weight (kg) over the twelve weeks.  Comparative subject intake 
habits are summarized in Table 2.  There were no significant differences between groups 
with the exception of other food items consumed with oats (p = 0.02).  Comparative 
percent subject lifestyle characteristics are summarized in Table 3.  There were no 
significant differences between groups, with the exception of percentage of those who are 
single (p = 0.01) and those who are partnered (p = .05). 
Comparative data from the Wisconsin Upper Respiratory Symptom Survey are 
summarized in Table 4.  Yeast ß-glucan demonstrated no statistically significant effect 
on the subjects for any of the variables (total number of days with symptoms, number of 
URTI episodes, total number of days until the occurence of an URTI episode, the average 
or maximum duration of an URTI episode, and the severity of URTI episodes). 
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DISCUSSION 
The purpose of this study was to examine the effects of a yeast β-glucan 
supplement on symptoms of upper respiratory tract infection in healthy, free-living, 
college-aged males.   
The combination of prior research in mice and immunnosuppressed humans 
suggests that β-glucan may have a beneficial effect on the immune system (Murphy et al., 
2008; Murphy et al., 2007; Davis et al., 2003).  However, research also implies that sleep, 
stress, nutritional behaviors, and physical activity has such diverse and profound effects 
on the immune system that any benefits from a beta-glucan supplement seen in free-
living, healthy persons, are likely to be insignificant (Beisel, 1996; Dinges et al., 1995; 
Cohen et al., 1991; Lac and Chamoux, 2003; Woods, 2005; Gleeson, 2007; Nieman, 
2003; Nieman 2007).  Previous research suggests that humans and mice have similar 
immune systems and should see similar effects with a β-glucan supplement (Dinges et al., 
1995; Gleeson, 2007; Nieman, 2003; Nieman 2007).  Along with this assertion is the 
theory of an immune ceiling from beneficial effects from proper amounts of sleep, stress, 
healthy nutritional behaviors, and healthy amounts of physical activity (Dinges et al., 
1995; Nieman, 2003; Nieman 2007).  The non-significant findings of the present study 
between the experimental and placebo groups agree with these theories. 
 
Limitations 
Although we aimed for socioeconomic diversity, our participants were volunteers 
and may not have been representative of cold-sufferers.  The data collected only applies 
to healthy, free-living, college-aged males.  Qualitative, self-reported survey data, may 
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have been biased.  The present research did not control for lifestyle habits, dietary habits, 
or for any exposure to disease or infection. 
 
CONCLUSION 
 The present research presents that a yeast β-glucan does not significantly decrease 
occurrence of symptoms of URTI in humans.  However, the population of healthy, free-
living, college-aged males tested in the present research may have an immune system 
with a maximum level of prevention of URTI.  Thus, any effects that a supplement may 
have on the immune system may be masked by these levels.  The limitations of the study 
may prevent any effect that yeast β-glucan has on the immune functioning of the subjects.  
It is recommended that future research on healthy, free-living subjects directs attention 
toward statistically controlling for dietary, sleep, exposure, stress, and physical activity 
habits. 
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